CytoMed Therapeutics Ltd

CytoMed Therapeutics Limited is a pre-clinical biopharmaceutical company developing cell-based immunotherapies targeting cancer and degenerative diseases. The company's pipeline centers on gamma delta T cell and natural killer T cell platforms, with its lead candidate CTM-N2D currently in Phase I clinical trials. This product combines expanded gamma delta T cells with chimeric antigen receptor technology designed to enhance anti-cancer cytotoxicity. Additional candidates include iPSC-gdNKT, a pluripotent stem cell-derived platform; CTM-GDT, an allogeneic gamma delta T cell therapy for broad-range cancer treatment; and CTM-MSC, an injectable mesenchymal stem cell product for cartilage injury.

The company operates through research collaborations and clinical development partnerships in Southeast Asia. CytoMed has established agreements with Sengkang General Hospital for CTM-MSC research and Phase I trials in Singapore, and with SunAct Cancer Institute for CTM-GDT clinical trial development. The company is incorporated and headquartered in Singapore with approximately 43 full-time employees, indicating early-stage operations focused on research and development activities.